Avidity touts early data, showing positive effect on progressive muscular disease while under partial FDA hold

An RNA biotech is looking to tout Phase I/II data as investors sent its share price on a rebound.

Avidity Biosciences said Wednesday that its …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Avid­i­ty touts ear­ly da­ta, show­ing pos­i­tive ef­fect on pro­gres­sive mus­cu­lar dis­ease while un­der par­tial FDA hold